

## **LISTING OF CLAIMS:**

1. **(Currently amended)** ~~The use of A method for the treatment of a person afflicted with SARS-CoV infection, comprising~~ a single botanical drug substance ~~(BDS)~~ or one or more botanical ingredients, obtained from a species of the genus *Scutellaria* selected from the group consisting of *Scutellaria baicalensis*, *S. amoena*, *S. barbata*, *S. discolor*, *S. hypericifolia*, *S. inbica*, *S. likiangensis*, *S. orthocalyx*, *S. rehderiana*, *S. scssiliflora* and *S. viscidula* ~~in the manufacture of a medicament~~ for the treatment of a patient with a SARS-CoV infection.

2. **(Currently amended)** ~~The use as claimed in claim 1~~ method recited in claim 1, wherein the medicament is a total extract of a *Scutellaria spp*.

3. **(Currently amended)** ~~The use as claimed in claim 1 or 2~~ method recited in claim 1, in which the medicament further comprises one or more excipients.

4. **(Currently amended)** ~~The use as claimed in any of the preceding claims~~ method recited in claim 1, wherein the substance administered is a botanical drug substance and is a standardised extract.

5. **(Currently amended)** ~~The use as claimed in claim 4~~ method recited in claim 4, wherein the botanical drug substance from the *Scutellaria spp* is standardised against a marker of baicalin and/ or baicalein.

6. **(Currently amended)** ~~The use as claimed in claims 4 or 5~~ method recited in claim 4, wherein the standardised extract is a dried ethanolic extract.

7. **(Currently amended)** ~~The use as claimed in any of claims 4-6~~ method recited in claim 4, wherein the standardised extract is a lyophilised extract.

8. **(Currently amended)** ~~The use as claimed in any of the preceding claims~~ method recited in claim 1, wherein the medicament is a botanical drug.

9. **(Currently amended)** The ~~use as claimed in claim 8~~ method recited in claim 8, wherein the botanical drug is packaged in a sachet.

10. **(Currently amended)** The ~~use as claimed in claim 9~~ method recited in claim 9, wherein the botanical drug is packaged with a dispensing container.

11. **(Currently amended)** The ~~use as claimed in claim 10~~ method recited in claim 10, wherein the dispensing container has a sealable lid.

12. **(Currently amended)** The ~~use as claimed in claim 3~~ method recited in claim 3, wherein the excipients comprise one or more gellants or thickeners comprising at least one xanthum gum having a particle size distribution such that 100% by weight of the particles pass a 60 mesh sieve, 95% by weight of the particles pass a 80 mesh sieve and 70% by weight of the particles pass a 200 mesh sieve; one or more fillers; and one or more wetting agents or surfactants.

13. **(Currently amended)** The ~~use as claimed in claim 1~~ method recited in claim 1, wherein the one or more botanical ingredients obtained from a species of the genus *Scutellaria* are plant flavenoids or synthetic equivalents thereof.

14. **(Currently amended)** The ~~use as claimed in claim 13~~ method recited in claim 13, wherein the plant flavenoids ~~is/are~~ are selected from the group consisting of baicalein, baicalin and wogonin.

15. **(Currently amended)** ~~The use of~~ A method of making a medicament, effective as an anti-viral treatment, comprising admixing a botanical raw material (BRM), a botanical drug substance (BDS) or one or more botanical ingredients, obtainable from a species of the genus *Scutellaria* in the manufacture of an anti-viral medicament.

16. **(Currently amended)** The ~~use as claimed in claim 15~~ method recited in claim 15, wherein the antiviral medicament is effective for the treatment of a patient with a positively stranded RNA viral infection.

17. **(Currently amended)** ~~The use as claimed in claim 15 or 16~~ method recited in claim 15, wherein the medicament is effective for the treatment of a patient with a SARS-CoV infection.

18. **(Original)** A suspension dosage medicament comprising a *Scutellaria* spp.

19. **(Currently amended)** The use of one or more botanical raw materials (~~BRM~~), one or more botanical drug substances (~~BDS~~), or one or more botanical ingredients obtainable from a species of the genus:

- (a) *Scutellaria*;
- (b) *Lonicera*;
- (c) *Forsythia*; or
- (d) *Rabdosia*

in the manufacture of a botanical drug (~~BD~~), or dietary supplement effective for the treatment of SARS-CoV.

20. **(Currently amended)** A suspension powder mixture of botanical raw materials effective as an anti-viral medicament, ~~comprising as botanicals comprising:~~

*Forsythia* in an amount by weight relative to the total weight of all the botanical raw materials of from 30 to 70 %,

*Lonicera* in an amount by weight relative to the total weight of all the botanical raw materials of from 12.5 to 37.5%, and

*Scutellaria* in an amount by weight relative to the total weight of all the botanical raw materials of from 12.5 to 37.5% and ~~as excipients~~:

one or more gellants or thickeners comprising at least one xanthum gum having a particle size distribution such that 100% by weight of the particles pass a 60 mesh sieve, 95% by weight of the particles pass a 80 mesh sieve and 70% by weight of the particles pass a 200 mesh sieve; one or more fillers; and one or more wetting agents or surfactants.

21. **(Currently amended)** ~~A~~ The suspension powder mixture as ~~claimed~~ claimed in claim 20 comprising standardised extracts of each of the *Forsythia*, *Lonicera* and *Scutellaria* species.

22. **(Currently amended)** A ~~The~~ suspension powder mixture as ~~claimed~~ recited in claim 21 wherein:

the *Forsythia spp* is standardised against a marker of Phillyrin;

the *Scutellaria spp* is standardised against a marker of either or both of Baicalin and Baicalein, and the

*Lonicera spp* is standardised against a marker of Chlorogenic acid and/ or caffeic acid.

23. **(Currently amended)** ~~The~~ A method of making a medicament for treating SARS-CoV, comprising the use of one or a plurality of ~~of~~ baicalin, baicalein, chlorogenic acid, forsythiaside, caffeic acid and phillyrin in ~~the manufacture of~~ a medicament effective for use in the treatment of SARS-CoV.

24. **(Currently amended)** A medicament effective as an anti-viral agent consisting essentially ~~of~~ of: botanical drug substances or botanical ingredients obtainable from a species of:

(a) *Scutellaria*;

(b) *Lonicera*;

(c) *Forsythia*; and

(d) *Rabdosia*

25. **(Currently amended)** A method of treating SARS-Co V comprising administering to a patient a medicament as claimed in ~~any of the preceding claims~~ claim 24.